FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387078100> ?p ?o ?g. }

• W4387078100 endingPage "1226" @default.
• W4387078100 startingPage "1219" @default.
• W4387078100 abstract "The United States Preventive Services Taskforce (USPSTF) recently recommended lowering the age for average-risk colorectal cancer (CRC) screening from 50 to 45 years. While initiating screening at age 45 versus 50 provides a greater opportunity for CRC early detection and prevention, the full profile of benefits, risks, and cost-effectiveness of expanding the screen-eligible population requires further evaluation.The costs and clinical outcomes for screening at age 45 for triennial multi-target stool DNA [mt-sDNA], and other non-invasive stool-based modalities (annual fecal immunochemical test [FIT] and annual fecal-occult blood test [FOBT]), were estimated using the validated CRC-AIM microsimulation model over a lifetime horizon. Test sensitivity and specificity inputs were based on 2021 USPSTF modeling analyses; adherence rates were based on published real-world data and the costs of the screening test, follow-up colonoscopies, complications, and CRC care were included. Outcomes are reported from the perspective of a United States payer as clinical, life-years gained (LYG), and incremental cost-effectiveness ratio (ICER); stool-based and follow-up colonoscopy adherence ranges were explored in one-way, probabilistic and threshold analyses.When compared to initiation of CRC screening at age 45 versus 50, all modalities reduced both the incidence of and mortality from CRC and increased LYG. Initiating CRC screening at age 45 was cost-effective with an ICER of $59,816 and $35,857 per quality-adjusted life year (QALY) for mt-sDNA versus FIT and FOBT, respectively. In the threshold analyses, at equivalent rates to stool-based screening, mt-sDNA was always cost-effective at a willingness-to-pay threshold of $100,000 per QALY versus FIT and FOBT.Initiating average-risk CRC screening at age 45 instead of age 50 increases the estimated clinical benefit by reducing disease burden while remaining cost-effective. Among stool-based screening modalities, mt-sDNA provides the most clinical benefit in a Commercial and Medicare population.Screening for colorectal cancer at an earlier age can provide additional benefits in terms of reducing disease complications and death. This study looked at the occurrence of disease complications and costs related to different types of colorectal cancer screening in 45 vs. 50 year old people. A model that has previously been used to project lifetime costs and disease complications in people receiving colorectal cancer screening was used in this study. We found that beginning screening at age 45 as compared to at age 50 reduced disease complications and death. In people who started screening at age 45, one particular screening type (multitarget stool DNA) was found to provide better economic value to a greater degree relative to other strategies. These findings were consistent even when many inputs into the model were changed over reasonable ranges. Therefore, our study helps show that starting screening in people at age 45 with average risk for developing colorectal cancer is beneficial by reducing disease complications and deaths, and that multitarget stool DNA is the strategy that provides the most benefits while being economically justifiable." @default.
• W4387078100 created "2023-09-28" @default.
• W4387078100 creator A5000682358 @default.
• W4387078100 creator A5017521990 @default.
• W4387078100 creator A5025315719 @default.
• W4387078100 creator A5032059107 @default.
• W4387078100 creator A5044304609 @default.
• W4387078100 creator A5045614803 @default.
• W4387078100 creator A5054683366 @default.
• W4387078100 creator A5061571868 @default.
• W4387078100 creator A5063732780 @default.
• W4387078100 creator A5079112958 @default.
• W4387078100 date "2023-10-06" @default.
• W4387078100 modified "2023-10-09" @default.
• W4387078100 title "The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and Medicare population" @default.
• W4387078100 cites W2050056063 @default.
• W4387078100 cites W2089300758 @default.
• W4387078100 cites W2100770509 @default.
• W4387078100 cites W2150332122 @default.
• W4387078100 cites W2159078264 @default.
• W4387078100 cites W2584886407 @default.
• W4387078100 cites W2592701528 @default.
• W4387078100 cites W2610507653 @default.
• W4387078100 cites W2805885226 @default.
• W4387078100 cites W2805893709 @default.
• W4387078100 cites W2932827579 @default.
• W4387078100 cites W2996207027 @default.
• W4387078100 cites W3003730688 @default.
• W4387078100 cites W3006480371 @default.
• W4387078100 cites W3007143291 @default.
• W4387078100 cites W3024655443 @default.
• W4387078100 cites W3116978750 @default.
• W4387078100 cites W3121008033 @default.
• W4387078100 cites W3134856831 @default.
• W4387078100 cites W3136969916 @default.
• W4387078100 cites W3160078921 @default.
• W4387078100 cites W3162019711 @default.
• W4387078100 cites W3212817510 @default.
• W4387078100 cites W4200461975 @default.
• W4387078100 cites W4231576061 @default.
• W4387078100 cites W4286256899 @default.
• W4387078100 cites W4383998850 @default.
• W4387078100 doi "https://doi.org/10.1080/13696998.2023.2260681" @default.
• W4387078100 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37752872" @default.
• W4387078100 hasPublicationYear "2023" @default.
• W4387078100 type Work @default.
• W4387078100 citedByCount "0" @default.
• W4387078100 crossrefType "journal-article" @default.
• W4387078100 hasAuthorship W4387078100A5000682358 @default.
• W4387078100 hasAuthorship W4387078100A5017521990 @default.
• W4387078100 hasAuthorship W4387078100A5025315719 @default.
• W4387078100 hasAuthorship W4387078100A5032059107 @default.
• W4387078100 hasAuthorship W4387078100A5044304609 @default.
• W4387078100 hasAuthorship W4387078100A5045614803 @default.
• W4387078100 hasAuthorship W4387078100A5054683366 @default.
• W4387078100 hasAuthorship W4387078100A5061571868 @default.
• W4387078100 hasAuthorship W4387078100A5063732780 @default.
• W4387078100 hasAuthorship W4387078100A5079112958 @default.
• W4387078100 hasBestOaLocation W43870781001 @default.
• W4387078100 hasConcept C112930515 @default.
• W4387078100 hasConcept C121608353 @default.
• W4387078100 hasConcept C126322002 @default.
• W4387078100 hasConcept C2778435480 @default.
• W4387078100 hasConcept C2779158730 @default.
• W4387078100 hasConcept C2908647359 @default.
• W4387078100 hasConcept C3019080777 @default.
• W4387078100 hasConcept C526805850 @default.
• W4387078100 hasConcept C71924100 @default.
• W4387078100 hasConcept C99454951 @default.
• W4387078100 hasConceptScore W4387078100C112930515 @default.
• W4387078100 hasConceptScore W4387078100C121608353 @default.
• W4387078100 hasConceptScore W4387078100C126322002 @default.
• W4387078100 hasConceptScore W4387078100C2778435480 @default.
• W4387078100 hasConceptScore W4387078100C2779158730 @default.
• W4387078100 hasConceptScore W4387078100C2908647359 @default.
• W4387078100 hasConceptScore W4387078100C3019080777 @default.
• W4387078100 hasConceptScore W4387078100C526805850 @default.
• W4387078100 hasConceptScore W4387078100C71924100 @default.
• W4387078100 hasConceptScore W4387078100C99454951 @default.
• W4387078100 hasIssue "1" @default.
• W4387078100 hasLocation W43870781001 @default.
• W4387078100 hasLocation W43870781002 @default.
• W4387078100 hasOpenAccess W4387078100 @default.
• W4387078100 hasPrimaryLocation W43870781001 @default.
• W4387078100 hasRelatedWork W1568428545 @default.
• W4387078100 hasRelatedWork W1981998263 @default.
• W4387078100 hasRelatedWork W2018977213 @default.
• W4387078100 hasRelatedWork W2166138786 @default.
• W4387078100 hasRelatedWork W2334644968 @default.
• W4387078100 hasRelatedWork W2762467226 @default.
• W4387078100 hasRelatedWork W2898124637 @default.
• W4387078100 hasRelatedWork W2931310522 @default.
• W4387078100 hasRelatedWork W4241271596 @default.
• W4387078100 hasRelatedWork W4318064709 @default.
• W4387078100 hasVolume "26" @default.
• W4387078100 isParatext "false" @default.
• W4387078100 isRetracted "false" @default.
• W4387078100 workType "article" @default.